布利莫德(选择性B细胞活化因子抑制剂)治疗系统性红斑狼疮的III期随机双盲安慰剂对照试验结果
442例抗核抗体或抗dsDNA阳性且SELENA-SLEDAI评分≥10的系统性红斑狼疮患者随机接受每周皮下布利莫德200 mg或安慰剂,主要终点第52周SRI-6未达到;布利莫德组激素减量成功比例显著更高,基线UPCR≥56.5 mg/mmol者中UPCR降低>50%和/或UPCR<56.5 mg/mmol的比例显著更高,并观察到自身抗体和B细胞下降、补体C3和C4升高;布利莫德耐受性良好。
要点
- 主要终点第52周SRI-6未达到,但布利莫德组激素减量成功比例显著更高。
- 基线UPCR≥56.5 mg/mmol者中,布利莫德组UPCR降低>50%和/或UPCR<56.5 mg/mmol的比例显著更高。
- 布利莫德耐受性良好,最常见不良事件为上呼吸道感染、尿路感染、注射部位红斑/反应和腹泻。
核心结论
- 尽管SRI-6终点未达到,布利莫德与成功的激素减量、蛋白尿降低和生物标志物应答相关。
研究设计与样本
- 随机、双盲、安慰剂对照III期试验,442例抗核抗体或抗dsDNA阳性且SELENA-SLEDAI评分≥10的系统性红斑狼疮患者随机接受每周皮下布利莫德200 mg或安慰剂。
- 从第8周起鼓励激素减量,主要终点为第52周SRI-6。
主要发现
- SRI-6主要终点未达到。
- 观察到统计学显著的激素节约效应,布利莫德组达到激素减量的受试者显著更多。
- 在基线UPCR≥56.5 mg/mmol的受试者中,布利莫德组达到UPCR降低>50%和/或UPCR<56.5 mg/mmol的比例显著更高。
- 布利莫德组观察到SLE自身抗体和B细胞下降、补体C3和C4升高。
- 布利莫德耐受性良好,最常见不良事件为上呼吸道感染、尿路感染、注射部位红斑/反应和腹泻。
关键数值与推荐
- 入组标准:抗核抗体或抗dsDNA阳性且SELENA-SLEDAI评分≥10,正在接受标准治疗。
- 布利莫德用法:每周皮下200 mg。
- 主要终点:第52周SRI-6。
- 激素减量鼓励从第8周开始。
临床怎么用
- 原文未据此给出推荐。
局限性
- SRI-6主要终点未达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeted inhibitors of B-cell activating factor (BAFF) have been evaluated in phase III trials in over 4000 patients with systemic lupus erythematosus (SLE). Post hoc analyses of these studies identify greater treatment effect in patients entering with higher disease activity, greater corticosteroid doses, anti double-stranded DNA (dsDNA) and low complement C3 or C4. OBJECTIVES: To evaluate the efficacy and safety of blisibimod, a BAFF inhibitor, in a population of patients with SLE enriched for high disease activity. METHODS: 442 patients with SLE with antinuclear antibodies or anti-dsDNA and Safety of Estrogen in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score ≥10 on standard-of-care medications were randomised to receive weekly subcutaneous blisibimod (200 mg) or placebo. Corticosteroid taper was encouraged from week 8. The primary end point was the week 52 SLE Responder Index-6 (SRI-6). RESULTS: The SRI-6 primary end point was not met. There was a statistically significant steroid-sparing effect, and significantly more blisibimod-treated subjects achieved corticosteroid taper. Increased blisibimod treatment effect on SRI-6 was observed in subjects who achieved a concomitant decrease in corticosteroid dose from baseline. In subjects with baseline urinary protein:creatinine ratio (UPCR) ≥56.5 mg/mmol, significantly higher proportions of blisibimod subjects achieved >50% reduction in UPCR and/or UPCR <56.5 mg/mmol. Reductions in SLE autoantibodies and B cells, and increases in complement C3 and C4 were observed with blisibimod.Blisibimod was well-tolerated. The most common adverse events were upper respiratory tract infection, urinary tract infection, injection site erythema/reaction and diarrhoea. CONCLUSIONS: Although the SRI-6 end point was not met, blisibimod was associated with successful steroid reduction, decreased proteinuria and biomarker responses. TRIAL REGISTRATION NUMBER: NCT01395745.
引用
- Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018. PMID: 29563108. doi:10.1136/annrheumdis-2018-213032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。